Biotechnology company Curis, Inc. (CRIS) announced Tuesday that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) with spliceosome mutations, such as SF3B1 and U2AF1, that drive expression of the long isoform of IRAK4 (IRAK4-L).
from RTT - Biotech https://ift.tt/2ZN8Dmq
via IFTTT
No comments:
Post a Comment